StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report sent to investors on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
TRACON Pharmaceuticals Stock Performance
Shares of NASDAQ:TCON opened at $0.04 on Tuesday. The firm has a market cap of $142,538.00, a price-to-earnings ratio of 0.01 and a beta of 1.43. The firm has a fifty day moving average price of $0.09 and a 200 day moving average price of $0.71. TRACON Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $14.75.
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The company had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
See Also
- Five stocks we like better than TRACON Pharmaceuticals
- 3 Small Caps With Big Return Potential
- Palantir Cracks $50, Is There Still Time to Get on Board?
- 3 Healthcare Dividend Stocks to Buy
- Insider Buying Signals Upside for These 3 Stocks
- What is the Nikkei 225 index?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
